Fulgent Genetics Inc
NASDAQ:FLGT
Fulgent Genetics Inc
NASDAQ:FLGT
Price:
21.74 USD
-1.67%
Market Closed
Updated:
May 21, 2024
EV/EBIT
Enterprise Value to EBIT
Enterprise Value to EBIT
-1.8
Current
1.8
Median
17.8
Industry
Lower
than median
Lower
than industry value
Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.
EV/EBIT
=-1.8
Enterprise Value
/
344.7m
EBIT
-192.5m
All Countries
| Market Cap | EV/EBIT | ||||
|---|---|---|---|---|---|
| US |
|
Fulgent Genetics Inc
NASDAQ:FLGT
|
649.8m USD | -1.8 | |
| US |
C
|
Cigna Group
XMUN:CGN
|
89B EUR | 12.8 | |
| US |
|
Cigna Corp
NYSE:CI
|
94.7B USD | 12.6 | |
| US |
|
CVS Health Corp
NYSE:CVS
|
71.9B USD | 8.8 | |
| US |
|
Laboratory Corporation of America Holdings
NYSE:LH
|
17.4B USD | 18.4 | |
| DE |
|
Fresenius SE & Co KGaA
XETRA:FRE
|
15.6B EUR | 16.5 | |
| US |
|
Quest Diagnostics Inc
NYSE:DGX
|
16B USD | 15.2 | |
| DE |
F
|
Fresenius Medical Care AG & Co KGaA
XETRA:FME
|
11.9B EUR | 15.7 | |
| DE |
|
Fresenius Medical Care AG
XMUN:FME
|
11.8B EUR | 15.6 | |
| US |
|
DaVita Inc
NYSE:DVA
|
12.4B USD | 12.1 | |
| US |
|
Oak Street Health Inc
NYSE:OSH
|
9.5B USD | -21.5 |
EV/EBIT Forward Multiples
Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.
1-Year Forward
EV/EBIT
-6.5
2-Years Forward
EV/EBIT
-5.6
3-Years Forward
EV/EBIT
-6.6
You don't have any saved screeners yet
